Understanding the AMP Results and So Much More

July 8, 2021
 
Dear Advocate,
 
We’re delighted to share our new publication Understanding Results of the AMP Trials. The first results of these landmark trials were announced in early 2021, but their implications will be echoing for years to come. This guide provides a foundation for advocates. 
 
The AMP trials evaluated the ability of a broadly neutralizing antibody (bNAb), called VRC01, to protect against HIV. The trials showed that VRC01 did not reduce the overall risk of acquiring HIV. However, VRC01 protected some individuals from infection by HIV viruses that were particularly vulnerable or “sensitive” to the antibody. Together these results mean AMP will inform future bNAb and vaccine studies. Read Understanding Results to learn more; listen to our Px Pulse podcast to dive into the AMP trials; and check out AVACer Daisy Ouya’s commentary on the AMP trials in the latest issue of IAVI’s Voices: Community Perspectives on Clinical Research. 
 
Also, in case you missed it, we’re highlighting a few other important resources to inform prevention advocacy: 

• More on Antibodies: IAVI and Wellcome recorded this webinar, Enhancing regulatory and policy frameworks for monoclonal antibodies (mAbs) in Africa: lessons learned from vaccines.
• All Things PrEP: The PrEP Learning Network hosted a webinar, Reframing PrEP Continuation: Highlights from the PMM-Jhpiego-USAID Think Tank on Prevention Effective Use Of PrEP.
• Put a Ring on It: The latest issue of the quarterly PROMISE-CHOICE Dapivirine Ring Newsletter features updates on advances of the Dapivirine Vaginal Ring. Find news from researchers, civil society, country implementers and invitations for workshops and other events.
• PEPFAR Needs a Leader: Devex recently published a commentary, US leadership matters in fighting AIDS, co-authored by AVAC’s Mitchell Warren and Emory University’s Carlos del Rio on the imperative for US President Joe Biden to end the delay in appointing PEPFAR’s next leader.
• What’s Your Pleasure: The HIV prevention research pipeline, including a wide array of molecules and modalities (backed up by a smokin’ DJ), was the subject of this webinar, What's Your Pleasure? Expanding Your Choices on the HIV Prevention Buffet. Access Code is required: iz5TqS2*

Best, 
AVAC